Scholars Central

Conference proceedingPublished Aug 2020

Oral Bioavailability enhancement of Ganciclovir by Chitosan Nanoparticles: Pharmacokinetics Studies

Authors: Rajendra Kotadiya

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ganciclovir (GCV), an acyclovir analogue, proved to have excellent antiviral activity against human Cytomegalovirus (CMV), a leading cause of congenital infections worldwide. Ganciclovir (GCV), given intravenously (i.v.) at 5 mg/kg of body weight once daily, or orally as capsules at 1,000 mg three times a day (TID), is the standard drug regimen for both the treatment and prevention of CMV disease. However, i.v. GCV is an inconvenient drug regimen for long-term use, requiring i.v. catheters and might leads to sepsis. Although GCV capsules are more convenient, the low relative bioavailability (6%) limits the concentrations in serum. In recent years, one promising delivery system with improved oral bioavailability, chitosan nanoparticles (CNs) have attracted considerable attention 1,2 . Hence, in present investigation various oral formulation containing GCV along with chitosan nanoparticles containing GCV have been developed and their in vivo studies using Wistar rats have been performed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmacokinetics & Experimental Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacokinetics & Experimental Therapeutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Rajendra Kotadiya”